Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Acq. announced
Quarterly results
|
|
ONCOSEC MEDICAL Inc (ONCS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/25/2017 |
8-K
| Quarterly results |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 12/08/2016 |
8-K
| Form 8-K - Current report |
| 10/13/2016 |
8-K
| Quarterly results |
| 12/09/2015 |
8-K
| Quarterly results |
| 10/14/2015 |
8-K
| Quarterly results |
| 12/08/2014 |
8-K
| Quarterly results|
Docs:
|
"OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015 SAN DIEGO — December 8, 2014 — — OncoSec Medical Inc. , a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014. FINANCIAL RESULTS For the quarter ended October 31, 2014, OncoSec Medical reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013. Research and development expenses were $2.5 million for the quarter ended October 31, 2014, compared to $0.8 million for the quarter ended October 31, 2013. This increase in research and development expenses was primarily a resu..." |
|
| 10/10/2014 |
8-K
| Quarterly results|
Docs:
|
"OncoSec Medical Announces YTD Results for Fiscal Year End 2014 SAN DIEGO — October 10, 2014 — OncoSec Medical Inc. , a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the fiscal year ended July 31, 2014. FINANCIAL RESULTS For the fiscal year ended July 31, 2014, OncoSec Medical reported a net loss of $12.0 million, or $0.06 per share, compared to a net loss of $7.2 million, or $0.07 per share, for the same period last year. The increase in net loss attributable to common stockholders for the year ended July 31, 2014, compared with the same period in 2013, resulted primarily from an increase in salary related expenses due to increased headcount as we continue to grow our company in support of our corporate goals and an increase in outs..." |
|
|
|